VEGFA and metastatic colorectal cancer: As prompted by the promising effect of targeted therapy with antiangiogenic agents on outcome of patients with metastatic colorectal cancer [35] and neovascular age-related macular degeneration [36], further preclinical and clinical trials are required to investigate the potential use of targeting VEGF as a therapeutic strategy adjunct to standard anti-TB treatment for TBPE.